Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - xultophy
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp616a2493f2581291ddc019d50fec7c8b
identifier: http://ema.europa.eu/identifier
/EU/1/14/947/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Xultophy 100 units/mL + 3.6 mg/mL solution for injection.
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-616a2493f2581291ddc019d50fec7c8b
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/14/947/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - xultophy
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What Xultophy is used for Xultophy is used to improve blood glucose (sugar) levels in adult patients with type 2 diabetes mellitus. You have diabetes because your body:
How Xultophy works
Xultophy contains two active substances that help your body control your blood sugar:
Xultophy and oral medicines for diabetes Xultophy is used with oral medicines for diabetes (such as metformin, pioglitazone and sulfonylurea medicines). It is prescribed when these medicines (used alone or with GLP-1 treatment or with basal insulin) are not enough to control your blood sugar levels.
If you use GLP-1 treatment You should stop your GLP-1 treatment prior to starting on Xultophy.
If you use insulin You should stop your insulin treatment prior to starting on Xultophy.
Do not use Xultophy
Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Xultophy.
Be especially aware of the following when using Xultophy:
Important things to know before you use this medicine: Tell your doctor if you:
Important things to know while you are using this medicine:
Skin changes at the injection site The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3 How to use Xultophy ). Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.
Children and adolescents Do not give this medicine to children or adolescents. There is no experience with Xultophy in children and adolescents under 18 years old.
Other medicines and Xultophy Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level this may mean your Xultophy dose has to change.
Listed below are the most common medicines, which may affect your Xultophy treatment.
Your blood sugar level may fall if you take:
Your blood sugar level may rise if you take:
Octreotide and lanreotide used for treatment of acromegaly (a rare illness with too much growth hormone). They may increase or decrease your blood sugar level.
Pioglitazone tablets used for the treatment of type 2 diabetes mellitus. Some patients with long- standing type 2 diabetes mellitus and heart disease or previous stroke, who were treated with pioglitazone and insulin, experienced the development of heart failure. Inform your doctor straight away if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).
Warfarin or other blood thinners medicines used to prevent clotting of the blood. Tell your doctor if you are taking warfarin or other blood thinners as you might need to have blood tests more often to measure how thick your blood is (called International Normalised Ratio or INR test).
Xultophy with alcohol If you drink alcohol, your need for Xultophy may change. Your blood sugar level may either rise or fall. You should therefore monitor your blood sugar level more often than usual.
Pregnancy and breast-feeding
Do not use Xultophy if you are pregnant or plan to become pregnant. Tell your doctor if you are pregnant, think you might be pregnant or are planning to have a baby. It is not known if Xultophy affects the baby.
Do not use Xultophy if you are breast-feeding. It is not known if Xultophy passes into breast milk.
Driving and using machines
Having low or high blood sugar can affect your ability to drive or use any tools or machines. If your blood sugar is low or high, your ability to concentrate or react might be affected. This could be dangerous to yourself or others. Ask your doctor whether you can drive if:
Important information about some of the ingredients of Xultophy
Xultophy contains less than 1 mmol sodium (23 mg) per dose. This means that the medicine is essentially sodium-free .
Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.
If you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use this pen without help. Get help from a person with good eyesight who is trained to use the Xultophy pre-filled pen.
Your doctor will tell you:
Your dose of Xultophy is administered as dose steps . The dose counter on the pen shows the number of dose steps.
Dosing time
How to handle Xultophy
Xultophy is a pre-filled dial-a-dose pen.
How to inject Before you use Xultophy for the first time, your doctor or nurse will show you how to inject.
Detailed instructions for use are on the other side of this leaflet.
Do not use Xultophy:
Use in elderly patients (65 years old or over) Xultophy can be used in elderly patients but if you are elderly you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.
If you have kidney or liver problems If you have kidney or liver problems, you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.
If you use more Xultophy than you should
If you use more Xultophy than you should, your blood sugar may get low (hypoglycaemia) or you may feel or be sick (nausea or vomiting). If your blood sugar gets low, see the advice in section 4 Low blood sugar (hypoglycaemia) .
If you forget to use Xultophy
If you forget a dose, inject the missed dose when discovering the mistake, ensuring a minimum of 8 hours between doses. If you discover that you missed your previous dose when it is time to take your next regular scheduled dose, do not take a double dose.
If you stop using Xultophy
Do not stop using Xultophy without talking to your doctor. If you stop using Xultophy this could lead to a very high blood sugar level, see the advice in section 4 High blood sugar (hyperglycaemia) .
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following serious side effects may happen with this medicine:
If you have a serious allergic reaction to any of the ingredients in Xultophy, stop using Xultophy and see a doctor straight away. The signs of a serious allergic reaction are:
local reactions spread to other parts of your body
you suddenly feel unwell with sweating
you have difficulty breathing
you get a fast heartbeat or feel dizzy.
Skin changes at the injection site: If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect up to 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes.
Other side effects include: Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Not known (frequency cannot be estimated from the available data)
General effects from diabetes treatment
Low blood sugar (hypoglycaemia)
Low blood sugar may happen if you:
Warning signs of low blood sugar these may come on suddenly Headache, slurred speech, fast heartbeat, cold sweat, cool pale skin, feeling sick (nausea), feeling very hungry, shaking, feeling nervous or worried, unusually tired, weak and sleepy or confused, difficulty concentrating, short-lasting changes in your sight.
What to do if you get low blood sugar:
What others need to do if you pass out:
Tell everyone you spend time with that you have diabetes. Tell them what could happen if your blood sugar gets low, including the risk of passing out.
Let them know that if you pass out, they must:
You may recover more quickly from passing out if you receive glucagon. This can only be given by someone who knows how to use it.
High blood sugar (hyperglycaemia)
High blood sugar may happen if you:
Warning signs of high blood sugar these normally appear gradually Flushed, dry skin, feeling sleepy or tired, dry mouth, fruity (acetone) breath, urinating more often, feeling thirsty, losing your appetite, feeling or being sick (nausea or vomiting). These may be signs of a very serious condition called ketoacidosis . This is a build-up of acid in the blood because the body is breaking down fat instead of sugar. If not treated, this could lead to diabetic coma and eventually death.
What to do if you get high blood sugar:
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the pen label and carton after EXP . The expiry date refers to the last day of that month.
Before opening Store in a refrigerator (2 C to 8 C). Keep away from the freezing element. Do not freeze.
During use Do not freeze. You can carry Xultophy with you and keep it at room temperature (no more than 30 C) or in a refrigerator (2 C to 8 C) for up to 21 days. The product should be thrown away 21 days after first opening.
Always keep the cap on the pre-filled pen when you are not using it in order to protect it from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Xultophy contains
What Xultophy looks like and contents of the pack Xultophy is a clear and colourless solution. Pack sizes of 1, 3, 5 and a multipack containing 10 (2 packs of 5) pens of 3 mL. Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer Novo Nordisk A/S Novo All
DK-2880 Bagsv rd, Denmark
Now turn over for information on how to use your pre-filled pen.
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-616a2493f2581291ddc019d50fec7c8b
Resource Composition:
Generated Narrative: Composition composition-en-616a2493f2581291ddc019d50fec7c8b
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/14/947/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - xultophy
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp616a2493f2581291ddc019d50fec7c8b
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp616a2493f2581291ddc019d50fec7c8b
identifier:
http://ema.europa.eu/identifier
/EU/1/14/947/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Xultophy 100 units/mL + 3.6 mg/mL solution for injection.
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en